Aevis Victoria SA (SWX:AEVS)
12.80
-0.05 (-0.39%)
Aug 21, 2026, 5:31 PM CET
Aevis Victoria Revenue
In the year 2025, Aevis Victoria had annual revenue of 1.04B CHF with 18.09% growth. Aevis Victoria had revenue of 507.03M in the half year ending December 31, 2025, with 25.18% growth.
Revenue
1.04B
Revenue Growth
+18.09%
P/S Ratio
1.04
Revenue / Employee
214.15K
Employees
4,870
Market Cap
1.09B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.04B | 159.76M | 18.09% |
| Dec 31, 2024 | 883.16M | 50.15M | 6.02% |
| Dec 31, 2023 | 833.02M | -133.85M | -13.84% |
| Dec 31, 2022 | 966.86M | 221.95M | 29.79% |
| Dec 31, 2021 | 744.92M | 119.97M | 19.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 62.96B |
| Novartis AG | 45.81B |
| Lonza Group AG | 6.87B |
| Galderma Group AG | 4.79B |
| Tecan Group AG | 870.53M |
| PolyPeptide Group AG | 423.58M |
| SKAN Group AG | 363.25M |
| Medartis Holding AG | 307.05M |
Aevis Victoria News
- 3 months ago - Aevis Victoria Slides: FY 2026 - Filings
- 3 months ago - Aevis Victoria Earnings release: Q1 2026 - Filings
- 5 months ago - Aevis Victoria Earnings Call Transcript: H2 2025 - Transcripts
- 5 months ago - Aevis Victoria Slides: H2 2025 - Filings
- 5 months ago - Aevis Victoria Annual report: H2 2025 - Filings
- 5 months ago - Aevis Victoria Earnings release: H2 2025 - Filings
- 10 months ago - Aevis Victoria Earnings release: Q3 2025 - Filings
- 1 year ago - Aevis Victoria Quarterly report: H1 2025 - Filings